• PDF / 169,597 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 65 Downloads / 197 Views

DOWNLOAD

REPORT

---

1 S

Bullous pemphigoid: 17 case reports In a retrospective study of 82 patients with bullous pemphigoid (BP) treated between January 2015 and December 2019, 17 patients (8 men and 9 women) aged 68–87 years were described, who developed BP during treatment with alogliptin, linagliptin, sitagliptin or vildagliptin for type II diabetes mellitus [DM; routes, dosages and outcomes not stated; not all times to reactions onsets stated]. The patients, who had type II DM, started receiving vildagliptin and linagliptin (n=1), alogliptin (n=2), sitagliptin (n=2), vildagliptin (n=7) and linagliptin (n=5). Concomitantly, 16 patients received metformin, insulin or unspecified sodium-glucosetransporter-2-inhibitor, sulfonylurea or thiazolidinedione. Eventually, they developed BP, with 7 patients developing BP at 0–16 months after the initiation of respective CD26-antigen-inhibitor therapy. Based on investigations, they was diagnosed with inflammatory BP (n=13) and non-inflammatory BP (n=4) secondary to vildagliptin and linagliptin (n=1), alogliptin (n=2), sitagliptin (n=2), vildagliptin (n=7) and linagliptin. (n=5). Therefore, all the patients were treated with unspecified systemic steroid. Mokos ZB, et al. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: A retrospective study. 803498066 Croatian Medical Journal 61: 93-99, No. 2, Apr 2020. Available from: URL: http://doi.org/10.3325/cmj.2020.61.93

0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 29 Aug 2020 No. 1819